Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 246

Results For "new"

5350 News Found

HCAH Kolkata Center achieves NABH Certification
News | August 15, 2024

HCAH Kolkata Center achieves NABH Certification

Becomes the first rehab & recovery center in east India to earn NABH accreditation


Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
News | August 15, 2024

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore


Marksans Pharma Q1 FY25 revenue up 18%
News | August 14, 2024

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%


Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
News | August 13, 2024

Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24


Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg
Drug Approval | August 13, 2024

Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals


Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland
News | August 13, 2024

Ashland completes second expansion of Viatel bioresorbable polymers manufacturing and R&D lab in Ireland

This project is supported by the Irish Government through IDA Ireland


Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Drug Approval | August 13, 2024

Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer

Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years


Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
News | August 13, 2024

Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr

Morepen Labs successfully raised Rs. 200 Crore through QIP


Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
News | August 12, 2024

Lupin Q1 FY25 profit up 77% at Rs. 801 Cr

Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore


Wockhardt Q1 FY25 revenue up 14%
News | August 12, 2024

Wockhardt Q1 FY25 revenue up 14%

EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year